Geviti, Telehealth Platform

Geviti is a Utah-based longevity and precision health company that launched with the goal of making biomarker-driven, physician-supervised health optimization accessible at a price point that does not require the income of a Silicon Valley executive. The company was founded on the observation that the longevity medicine market — with its $15,000–$85,000 per year executive health programs and $300+/month telehealth memberships — serves a narrow demographic, while the vast majority of health-motivated Americans have no access to comprehensive biomarker monitoring or the prescription therapies that can meaningfully improve how they age. Geviti's answer is a tiered membership model starting at $54/month, built around what the company calls the Longeviti Panel — a twice-yearly blood draw analyzing more than 90 biomarkers spanning hormones, metabolic health, cardiovascular risk, inflammation, nutrient status, and biological aging markers. This is significantly more comprehensive than the panels offered at most primary care visits and comparable in depth to diagnostics at much higher-priced platforms. The twice-yearly frequency — rather than the quarterly retesting of premium competitors — is part of what keeps the cost accessible. The most strategically interesting aspect of Geviti's model is its wholesale prescription pricing structure. Rather than marking up compounded hormones, peptides, and GLP-1 medications by the industry-standard 200–300%, Geviti offers members access to prescriptions at manufacturer-level pricing. For patients who are on multiple protocols — testosterone, a GH peptide, and a GLP-1 medication, for example — this can represent hundreds of dollars per month in savings compared to other cash-pay telehealth platforms, even after accounting for the membership fee. It inverts the typical telehealth economics where the consultation is cheap but the medications are the hidden cost. In December 2025, Geviti announced expansion to 47 states following its $8.5 million funding round, adding a new membership tier and significantly scaling its clinical operations. The company is actively working toward all-50-state coverage. The Geviti app serves as the central hub for members to view their biomarker trends, receive supplement and protocol recommendations, and communicate with Longevity Specialists. The platform also generates personalized supplement stacks — branded as the Longeviti Blend — formulated based on each member's specific biomarker deficiencies rather than generic wellness formulas. For patients who are ready to treat their health as a data problem — collecting rigorous information twice a year, acting on it clinically, and tracking improvement over time — Geviti offers a compelling combination of clinical depth and price accessibility that few competitors match. The company was founded on the observation that the longevity medicine market — with its $15,000–$85,000 per year executive health programs and $300+/month telehealth memberships — serves a narrow demographic, while the vast majority of health-motivated Americans have no access to comprehensive biomarker monitoring or the prescription therapies that can meaningfully improve how they age. Geviti's answer is a tiered membership model starting at $54/month, built around what the company calls the Longeviti Panel — a twice-yearly blood draw analyzing more than 90 biomarkers spanning hormones, metabolic health, cardiovascular risk, inflammation, nutrient status, and biological aging markers. This is significantly more comprehensive than the panels offered at most primary care visits and comparable in depth to diagnostics at much higher-priced platforms. The twice-yearly frequency — rather than the quarterly retesting of premium competitors — is part of what keeps the cost accessible. The most strategically interesting aspect of Geviti's model is its wholesale prescription pricing structure. Rather than marking up compounded hormones, peptides, and GLP-1 medications by the industry-standard 200–300%, Geviti offers members access to prescriptions at manufacturer-level pricing. For patients who are on multiple protocols — testosterone, a GH peptide, and a GLP-1 medication, for example — this can represent hundreds of dollars per month in savings compared to other cash-pay telehealth platforms, even after accounting for the membership fee. It inverts the typical telehealth economics where the consultation is cheap but the medications are the hidden cost. In December 2025, Geviti announced expansion to 47 states following its $8.5 million funding round, adding a new membership tier and significantly scaling its clinical operations. The company is actively working toward all-50-state coverage. The Geviti app serves as the central hub for members to view their biomarker trends, receive supplement and protocol recommendations, and communicate with Longevity Specialists. The platform also generates personalized supplement stacks — branded as the Longeviti Blend — formulated based on each member's specific biomarker deficiencies rather than generic wellness formulas. For patients who are ready to treat their health as a data problem — collecting rigorous information twice a year, acting on it clinically, and tracking improvement over time — Geviti offers a compelling combination of clinical depth and price accessibility that few competitors match.